Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EPS (Weighted Average and Diluted) (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$1.05 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 275.0% to -$1.05 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 through Dec 2025, down 42.86% year-over-year, with the annual reading at -$5.11 for FY2023, 93.1% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.05 at Aytu Biopharma, down from -$0.08 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.21 in Q1 2025, with the low at -$35.9 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$4.77, with a median of -$0.77 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 6117.14% in 2021, then soared 140.38% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$8.74 in 2021, then surged by 75.4% to -$2.15 in 2022, then surged by 105.12% to $0.11 in 2023, then plummeted by 354.55% to -$0.28 in 2024, then crashed by 275.0% to -$1.05 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$1.05, -$0.08, and $0.21 for Q4 2025, Q3 2025, and Q1 2025 respectively.